Patent application EP16305697A (EP), filed 2016-06-10
Publication number: EP3254692A1
Title: MULTIVALENT RECOMBINANT SPV
Abstract: [0001]    The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are doubly defective for IL18bp and TK genes, and comprise at least one foreign gene cloned into defective TK gene sequence. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection.
IPC codes: A61K  39/    12            A I
C12N  15/    86            A I
Claims: number: 1
text: A recombinant swinepox virus (rSPV) having at least a first and a second defective viral genes, wherein the first defective viral gene is IL18bp gene and the second defective viral gene is the Thymidine Kinase (TK) or Ankirin Repeat Protein (ARP) gene.
number: 2
text: The rSPV of claim 1, wherein said rSPV comprises a deletion of at least 50bp in the TK gene sequence and a deletion of at least 50bp in the IL18bp gene sequence.
number: 3
text: The rSPV of claim 1, which comprises a deletion of at least 100bp in the TK gene sequence and a deletion of at least 100bp in the IL18bp gene sequence, preferably a deletion of at least 200bp in the TK gene sequence and a deletion of at least 200bp in the IL18bp gene sequence, even more preferably a deletion of at least 300bp in the TK gene sequence and a deletion of at least 300bp in the IL18bp gene sequence.
number: 4
text: The rSPV of claim 1, wherein said rSPV comprises a deletion of at least 50bp in the ARP gene sequence and a deletion of at least 50bp in the IL18bp gene sequence.
number: 5
text: The rSPV of anyone of claims 1 to 4, which further comprises a first foreign gene sequence, located in place of the defective viral TK, ARP or IL18bp gene sequence.
number: 6
text: The rSPV of anyone of claims 1 to 5, wherein the rSPV genome comprises a deletion of at least 100bp in the TK gene sequence and wherein the first foreign gene sequence is located in said deletion.
number: 7
text: The rSPV of anyone of claims 1 to 6, wherein said rSPV comprises a first foreign gene sequence located in place of the deleted viral TK gene sequence, and a second foreign gene sequence located in place of the deleted viral IL18bp gene sequence.
number: 8
text: The rSPV of anyone of claims 1 to 5, wherein said rSPV comprises a first foreign gene sequence located in place of the deleted viral ARP gene sequence, and a second foreign gene sequence located in place of the deleted viral IL18bp gene sequence.
number: 9
text: The rSPV of anyone of the preceding claims, wherein the first and/or second foreign gene sequences encode an antigen, preferably a PCV2 antigen.
number: 10
text: The rSPV of anyone of the preceding claims, wherein the first and/or second foreign gene sequences encode a PCV2 capsid antigen, preferably a PCV2 ORF2 protein or peptide.
number: 11
text: The rSPV of any one of the preceding claims, wherein each of the first and/or second foreign gene sequences contains a transcriptional promoter.
number: 12
text: The rSPV of claim 11, wherein each promoter is selected from the vaccinia virus 7.5-kD promoter (P7.5k), 11-kD promoter (P11k), or 28-kD promoter (P28k), an artificial synthetic Poxvirus promoter (Ps), the chicken beta-actin (Bac) promoter or a derivative thereof, the Pec promoter, the Murine Cytomegalovirus (Mcmv) immediate-early (ie)1 promoter, the Human Cytomegalovirus promoter (Hcmv), the Simian virus (SV)40 promoter, and the Raus Sarcoma virus (RSV) promoter, or any fragments thereof which retain a promoter activity.
number: 13
text: A rSPV of any one of the preceding claims, comprising a first nucleic acid sequence encoding a PCV2 antigen inserted in place of the deleted TK gene sequence of the rSPV genome, and a second nucleic acid sequence encoding a PCV2 antigen inserted in place of the deleted IL18bp gene sequence of the rSPV genome.
number: 14
text: A recombinant swinepox virus (rSPV) having a defective viral IL18bp gene.
number: 15
text: A nucleic acid molecule comprising the genome of a rSPV of any one of the preceding claims.
number: 16
text: A host cell comprising a rSPV of any one of claims 1 to 14 or a nucleic acid molecule of claim 15.
number: 17
text: A method for producing a rSVP of any one of claims 1 to 13, comprising infecting a competent cell with a nucleic acid molecule of claim 14 and collecting the rSVP.
number: 18
text: A composition comprising a rSVP of any one of claims 1 to 10 and an excipient.
number: 19
text: A composition of claim 14, which is a vaccine.
number: 20
text: A rSPV of any one of claims 1 to 10, for use for immunizing a porcine against a pathogen.
number: 21
text: A vaccination kit for immunizing a porcine which comprises the following components:
Office action: search_report, dated 2017-12-13
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: US5651972A
ref_type: patent
severity: background
ref_id: EP2015080468W
ref_type: patent
severity: background
ref_id: JP2003111591A
ref_type: patent
severity: background
ref_id: WO2014167060A1
ref_type: patent
severity: background
ref_id: EP1741785A1
ref_type: patent
severity: background
ref_id: WO2010061000A1
ref_type: patent
severity: background
ref_id: EP1816200A1
ref_type: patent
severity: background
ref_id: EP1036180A2
ref_type: patent
severity: background
ref_id: EP2225367A1
ref_type: patent
severity: background
ref_id: WO2013030320A1
ref_type: patent
severity: background
ref_id: US5387519A
ref_type: patent
severity: background
ref_id: WO2007030668A2
ref_type: patent
severity: background
ref_id: - OGAWA R. ET AL., VACCINE, vol. 8, 1990, pages 486 - 490
ref_type: npl
severity: background
ref_id: - HSU, K. H. ET AL., VACCINE, vol. 12, 1994, pages 607 - 612
ref_type: npl
severity: background
ref_id: - SHIN, M. -F. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 5867 - 5870
ref_type: npl
severity: background
ref_id: - VAN ZIJL M. ET AL., J. VIROL., vol. 65, 1991, pages 2761 - 2765
ref_type: npl
severity: background
ref_id: - MORGAN R. W. ET AL., AVIAN DIS., vol. 36, 1992, pages 858 - 870
ref_type: npl
severity: background
ref_id: - DAVISON A. J. ET AL., J. MOL. BIOL., vol. 210, no. 4, 1989, pages 749 - 69
ref_type: npl
severity: background
ref_id: - BERTHOLET ET AL., PROC. NAT. ACAD. SCI., vol. 82, 1985, pages 2096 - 2100
ref_type: npl
severity: background
ref_id: - WEIR J. P.; MOSS B., J. VIROL., vol. 61, 1987, pages 75 - 80
ref_type: npl
severity: background
ref_id: - ROSS L. J., GEN. VIROL., vol. 74, 1993, pages 371 - 377
ref_type: npl
severity: background
ref_id: - ALTING-MESS M. A., NUCLEIC ACIDS RES., vol. 17, 1989, pages 9494
ref_type: npl
severity: background
ref_id: - GUNNING P., PROC. NATL. ACAD. SCI., vol. 84, 1987, pages 4931 - 4835
ref_type: npl
severity: background
ref_id: - KOST A. T., NUCLEIC ACIDS RES., vol. 11, 1983, pages 8287 - 8301
ref_type: npl
severity: background
ref_id: - SPITZNER J. R., NUCLEIC ACIDS RES., vol. 18, 1990, pages 1 - 11
ref_type: npl
severity: background
ref_id: - FIEK A. ET AL., NUCLEIC ACIDS RES., vol. 20, 1992, pages 1785
ref_type: npl
severity: background
ref_id: - "Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 5371 1", August 1996, article "Program Manual for the Wisconsin Package, Version 8"
ref_type: npl
severity: background
ref_id: - NEEDLEMAN, S. B.; WUNSCH, CD., JOURNAL OF MOLECULAR BIOLOGY, vol. 48, 1970, pages 443 - 453
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual, 2nd edition,", 1989, COLD SPRING HARBOUR
ref_type: npl
severity: background
ref_id: - A.J. DAVISON; B. MOSS, J. MOL. BIOL., vol. 210, 1989, pages 771 - 784
ref_type: npl
severity: background
ref_id: - J. VIROL. METHODS, vol. 122, no. 2, 15 December 2004 (2004-12-15), pages 171 - 178
ref_type: npl
severity: background
ref_id: WO2016097281A1
ref_type: patent
severity: background
ref_id: WO2014167060A1
ref_type: patent
severity: background
ref_id: WO2015027163A1
ref_type: patent
severity: background
ref_id: - JULIANA FALIVENE ET AL: "Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein", PLOS ONE, vol. 7, no. 2, 22 February 2012 (2012-02-22), pages e32220, XP055330698, DOI: 10.1371/journal.pone.0032220
ref_type: npl
severity: background
ref_id: WO2014167060
ref_type: patent
severity: obviousness
ref_id: WO2015027163
ref_type: patent
severity: background
ref_id: WO2016097281
ref_type: patent
severity: novelty_destroying
ref_id: - JULIANA FALIVENE ET AL, "Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein", PLOS ONE, (20120222), vol. 7, no. 2, doi:10.1371/journal.pone.0032220, page e32220, XP055330698 [Y] 1-6,8-21 * the whole document *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-12-13)